pharma operations – Page 47

Specification tightening without data during inspection review – inspection-ready stability narrative

Addressing Specification Tightening Issues Without Data During Inspection Reviews In the pharmaceutical industry, the integrity of stability data plays a pivotal role in regulatory compliance and product lifecycle management. A…

Bracketing justification inadequate during submission support – regulatory deficiency prevention

Dealing with Inadequate Bracketing Justification During Submission Support: A Comprehensive Investigation Pharmaceutical manufacturers often encounter instances where the justification for bracketing during stability studies is deemed inadequate during regulatory submissions.…

Stability failure misinterpreted during post-approval commitment – inspection-ready stability narrative

Assessing Stability Failure Misinterpretations During Post-Approval Commitments The complexities involved in stability studies can sometimes lead to misinterpretations of results, especially during the post-approval phase. This can create significant risks…

Process knowledge not captured during transfer to manufacturing – regulatory scrutiny implications

Understanding the Implications of Uncaptured Process Knowledge During Manufacturing Transfer The successful transfer of process knowledge from R&D to manufacturing is critical to maintain product quality and compliance. However, lapses…

Design space poorly justified during comparability assessment – how to ensure smooth tech transfer

Managing Poorly Justified Design Space in Comparability Assessments for Effective Tech Transfer In the world of pharmaceutical manufacturing and quality assurance, the process of comparability assessments is crucial during tech…

Process knowledge not captured during scale-up – CAPA during development lifecycle

Understanding the Impact of Missing Process Knowledge During Scale-Up in Pharma Development In the pharmaceutical landscape, scale-up processes are critical for transitioning from laboratory to commercial production. However, the failure…

Scale-up risk not identified during scale-up – regulatory scrutiny implications

Identifying and Addressing Scale-Up Risks During Pharmaceutical Development In the pharmaceutical industry, the transition from laboratory-scale to commercial-scale manufacturing can convey various risks that, if unaddressed, may lead to regulatory…

Scale-up risk not identified during comparability assessment – regulatory scrutiny implications

Identifying Scale-Up Risks During Comparability Assessments to Avoid Regulatory Scrutiny In pharmaceutical manufacturing, the complexity of transitioning from lab-scale to commercial-scale production can introduce significant risks, particularly if not identified…

Process knowledge not captured during pilot scale – regulatory scrutiny implications

Implications of Uncaptured Process Knowledge During Pilot Scale for Regulatory Compliance In the competitive pharmaceutical landscape, maintaining stringent adherence to regulatory standards is paramount. A common pitfall occurs when critical…

Method development instability during scale-up – data package improvements for filing

“`html Addressing Method Development Challenges During Scale-Up: An Investigative Approach to Data Package Improvements Method development instability during scale-up can lead to significant challenges in pharmaceutical manufacturing, impacting product quality,…

Tech transfer readiness gaps during pilot scale – CAPA during development lifecycle

Identifying and Addressing Tech Transfer Readiness Gaps in Pilot Scale Development In the pharmaceutical industry, tech transfer readiness during pilot scale development is critical for ensuring a seamless transition between…

Design space poorly justified during pilot scale – CAPA during development lifecycle

Addressing Poor Justification of Design Space During the Pilot Scale: A Structured CAPA Approach The pharmaceutical industry often faces challenges related to design space justifications during the pilot scale of…